{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:01:37Z","timestamp":1790121697790,"version":"4.0.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The development of selective GR agonist and modulators (SEGRAMs) aimed to minimize the adverse effects of chronic glucocorticoid treatment (e.g., hyperglycemia and osteoporosis) by separating the transactivation and transrepression activities of the glucocorticoid receptor (GR). Herein we report the pharmacologic profile of clinical candidate GRM-01, a novel, orally available, non-steroidal SEGRAM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      GR, progesterone receptor (PR), and mineralocorticoid receptor (MR) binding and reporter gene assays were conducted to determine GRM-01 potency and selectivity. Anti-inflammatory effects were investigated\n                      <jats:italic>in vitro<\/jats:italic>\n                      using functional assays in rat and human whole blood, human lung cells, and primary fibroblast-like synoviocytes from human donors with rheumatoid arthritis.\n                      <jats:italic>In vitro<\/jats:italic>\n                      assays measured tyrosine aminotransferase [TAT] activity in human hepatocytes and osteoprotegerin release from human osteoblasts as markers of glucose and bone metabolism, respectively.\n                      <jats:italic>In vivo<\/jats:italic>\n                      studies examined the effect of GRM-01 on biomarkers in a rat model of inflammation and on cortisol levels in Cynomolgus monkeys. Animal pharmacokinetics (PK) for GRM-01 were determined and used to predict its human PK.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GRM-01 is a potent and selective ligand of human GR versus human PR and MR (inhibition constant = 12 vs. 3,700 and &amp;gt;10,000\u00a0nM, respectively). GRM-01 displayed partial induction (transactivation) at the GR (half-maximal effective concentration [EC\n                      <jats:sub>50<\/jats:sub>\n                      ] = 60.2 nM, efficacy 31.8%) versus prednisolone (EC\n                      <jats:sub>50<\/jats:sub>\n                      = 24.3 nM, efficacy 80.5%). GRM-01 demonstrated anti-inflammatory efficacy, inhibiting tumor necrosis factor-\u03b1 and interferon-\u03b3 release in whole blood assays, and interleukin-6 release in cellular assays. GRM-01 weakly increased TAT activity in HepG2 cells (efficacy 14.0% vs. 92.4% with prednisolone) and partially inhibited osteoprotegerin release in MG-63 cells (by 58% vs. 100%).\n                      <jats:italic>In vivo<\/jats:italic>\n                      , GRM-01 dose-dependently reduced rat ankle swelling, had anti-nociceptive effects, and did not increase blood glucose. In Cynomolgus monkeys, GRM-01 dose-dependently reduced plasma cortisol. Animal PK found that GRM-01 had high oral bioavailability, generally low clearance, and good tissue partitioning. The predicted human total plasma clearance of GRM-01 was 0.25\u00a0mL\/min\/kg, volume of distribution 2.124\u00a0L\/kg, and half-life \u223c98\u00a0h.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GRM-01 displays a favorable preclinical pharmacologic profile consistent with a SEGRAM, and based on this is currently in Phase 1 development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1542351","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:07:06Z","timestamp":1741147626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel selective glucocorticoid receptor modulator GRM-01 demonstrates dissociation of anti-inflammatory effects from adverse effects on glucose and bone metabolism"],"prefix":"10.3389","volume":"16","author":[{"given":"Florian","family":"Jakob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hennen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gautrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feras","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/bcp.14679","article-title":"Is there a safe and effective way to wean patients off long-term glucocorticoids?","volume":"87","author":"Baker","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","article-title":"Views on glucocorticoid therapy in rheumatology: the age of convergence","volume":"16","author":"Buttgereit","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0140-6736(05)17989-6","article-title":"Optimised glucocorticoid therapy: the sharpening of an old spear","volume":"365","author":"Buttgereit","year":"2005","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e000889","DOI":"10.1136\/rmdopen-2018-000889","article-title":"Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study","volume":"5","author":"Buttgereit","year":"2019","journal-title":"RMD Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"B6","first-page":"805","article-title":"Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol","volume":"37","author":"Clark","year":"1996","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00011-019-01279-z","article-title":"Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset","volume":"68","author":"Damsker","year":"2019","journal-title":"Inflamm. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/j.1552-4604.1988.tb03105.x","article-title":"Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses","volume":"28","author":"Ferry","year":"1988","journal-title":"J. Clin. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nyas.13435","article-title":"Insulin regulation of gluconeogenesis","volume":"1411","author":"Hatting","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/s2665-9913(19)30103-1","article-title":"Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials","volume":"2","author":"Hegelund Myrb\u00e4ck","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ejphar.2017.10.019","article-title":"Comparative analysis of ginsenosides in human glucocorticoid receptor binding, transactivation, and transrepression","volume":"815","author":"Hu","year":"2017","journal-title":"transactivation, transrepression"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1210\/en.2010-1447","article-title":"The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation","volume":"152","author":"Hu","year":"2011","journal-title":"Endocrinology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.bone.2005.10.004","article-title":"Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells","volume":"38","author":"Humphrey","year":"2006","journal-title":"Bone"},{"key":"B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Programs Biomed."},{"key":"B18","doi-asserted-by":"publisher","first-page":"115145","DOI":"10.1016\/j.biopha.2023.115145","article-title":"Biased regulation of glucocorticoid receptors signaling","volume":"165","author":"Mao","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.3390\/ijms24065173","article-title":"New insights into the role of synovial fibroblasts leading to joint destruction in rheumatoid arthritis","volume":"24","author":"Matsuda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","article-title":"Non-genomic effects of glucocorticoids: an updated view","volume":"40","author":"Panettieri","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1134\/s0006297908030103","article-title":"Role of glucocorticoids and resident liver macrophages in induction of tyrosine aminotransferase","volume":"73","author":"Panin","year":"2008","journal-title":"Biochem. (Mosc)."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1021\/acs.jmedchem.7b01690","article-title":"Discovery of a novel oral glucocorticoid receptor modulator (AZD9567) with improved side effect profile","volume":"61","author":"Ripa","year":"2018","journal-title":"J. Med. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/cpdd.411","article-title":"In vitro and in vivo investigation of potential for complex CYP3A interaction for PF-00251802 (Dagrocorat), a novel dissociated agonist of the glucocorticoid receptor","volume":"7","author":"Ripp","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.1016\/s0021-9258(18)60611-8","article-title":"Resolution of high and low affinity progesterone receptors from human breast carcinoma T47D cells","volume":"263","author":"Sarup","year":"1988","journal-title":"J. Biol. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1359\/jbmr.041233","article-title":"Influence of glucocorticoids on human osteoclast generation and activity","volume":"20","author":"Sivagurunathan","year":"2005","journal-title":"J. Bone Min. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pharmthera.2015.05.001","article-title":"Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds","volume":"152","author":"Sundahl","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1111\/cts.13624","article-title":"AZD9567 versus prednisolone in patients with active rheumatoid arthritis: a phase IIa, randomized, double-blind, efficacy, and safety study","volume":"16","author":"Van Laar","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","article-title":"The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis","volume":"79","author":"Van Staa","year":"2006","journal-title":"Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respir. Care."},{"key":"B30","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1530\/JOE-17-0361","article-title":"Animal models to explore the effects of glucocorticoids on skeletal growth and structure","volume":"236","author":"Wood","year":"2018","journal-title":"J. Endocrinol."},{"key":"B31","first-page":"1","volume-title":"Addendum to \u201cThe use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances\u201d WHO\/EMP\/RHT\/TSN\/2018","year":"2024"},{"key":"B32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/ijms23010377","article-title":"Animal model for glucocorticoid induced osteoporosis: a systematic review from 2011 to 2021","volume":"23","author":"Xavier","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1542351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:07:10Z","timestamp":1741147630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1542351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":32,"alternative-id":["10.3389\/fphar.2025.1542351"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1542351","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"article-number":"1542351"}}